BioCentury
ARTICLE | Clinical News

Tavocept misses Phase III endpoints

March 19, 2008 12:51 AM UTC

BioNumerik (San Antonio, Texas) said IV Tavocept ( BNP7787) did not meet the primary endpoint of preventing and reducing the severity of sporadic and cumulative neuropathy vs. placebo in a Japanese Ph...